search
Back to results

Trial of Low Field Magnetic Stimulation Augmentation of Antidepressant Therapy in Treatment-Resistant Depression (RAPID)

Primary Purpose

Treatment Resistant Depression

Status
Completed
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Low Field Magnetic Stimulation (LFMS)
Sham LFMS
Sponsored by
Massachusetts General Hospital
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Treatment Resistant Depression focused on measuring Depression, Treatment Resistant Depression

Eligibility Criteria

18 Years - 65 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Male or female, 18-65 years old
  • Diagnosed with Major Depressive Disorder (MDD) and currently experiencing a Major Depressive Episode (MDE) of at least eight weeks
  • A participant has Treatment Resistant Depression (TRD) of the current MDE
  • Good general health
  • For female participants, status of non-childbearing potential or use of an acceptable form of birth control
  • Body mass index between 18-40 kg/m2
  • Concurrent psychotherapy will be allowed if the type and frequency of the therapy has been stable for at least three months prior to screening and is expected to remain stable during participation in the study
  • Concurrent hypnotic therapy will be allowed if the therapy has been stable for at least 4 weeks prior to screening and is expected to remain stable during the subject's participation in the study
  • Participant must be able to lie flat for 20 minutes

Exclusion Criteria:

  • A woman of childbearing potential who is not willing to use one of the specified forms of birth control during the study
  • Pregnant or breastfeeding
  • A woman with a positive pregnancy test at screening or baseline
  • Participant has TRD of the current MDE with failure to achieve a satisfactory response, as perceived by the subject, to more than 3 treatment courses of a therapeutic dose of an antidepressant therapy of at least eight weeks duration
  • Participant has a current diagnosis of a Substance Use Disorder with the exception of nicotine dependence, at screening or within six months prior to screening
  • Current diagnosis of Axis I disorders other than Generalized Anxiety Disorder, Social Anxiety Disorder, Panic Disorder, Specific Phobia, Post Traumatic Stress Disorder or Complicated Grief (unless one of these is comorbid and clinically unstable, and/or the focus of the participant's treatment for the past six months or more).
  • Subject has a history of schizophrenia or schizoaffective disorders, any history of psychotic symptoms or is on antipsychotic medication for the treatment of psychotic symptoms
  • Subject has a history of eating disorders within five years of screening
  • Subject has any Axis I or Axis II Disorder, which at screening is clinically predominant to their MDD or has been predominant at any time within six months prior to screening
  • The participant is considered at significant risk for suicide during the study
  • Subject has had electroconvulsive therapy in the current episode of depression
  • Subject has had Transcranial Magnetic Stimulation or has received treatment with other experimental devices for the treatment of the current episode of depression
  • Subject has received Vagus Nerve Stimulation at any time
  • Dementia, delirium, amnestic, or other cognitive disorders
  • There is a clinically significant abnormality on the screening physical examination
  • Participation in any clinical trial with an investigational drug or device within the past month or concurrent to study participation
  • Known history or current episode of:

    --Uncontrolled hypertension, Recent myocardial infarction (within one year) or a history of more than one myocardial infarction, Syncopal event within the past year, Congestive heart failure, Angina pectoris

  • Lifetime history of surgical procedures involving the brain or meninges, encephalitis, meningitis, degenerative central nervous system disorder (e.g., Alzheimer's or Parkinson's Disease), epilepsy, mental retardation, any other disease/procedure/accident/intervention associated with significant injury to or malfunction of the central nervous system, or a history of significant head trauma within the past two years.
  • Lab abnormalities are present
  • History of hypothyroidism and has been on a stable dosage of thyroid replacement medication for less than six months prior to screening
  • Hisotry of hyperthyroidism which was treated (medically or sugically) less than six months prior to screening
  • Any current or past history of any physical condition which in the investigator's opinion might put the subject at risk or interfere with the interpretation of study results
  • History of positive screening urine test for drugs of abuse
  • Patient with any non-removable stimulation device such as neurostimulators, pacemakers and cochlear implants
  • Patients requiring treatment with excluded concomitant medications
  • Patients who cannot be in a MRI
  • Patients who are currently using a metal intrauterine device (IUD)

Sites / Locations

  • University of Alabama at Birmingham
  • Yale University
  • Emory University
  • Massachusetts General Hospital
  • Mount Sinai School of Medecine
  • University of Texas Southwestern

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm Type

Active Comparator

Placebo Comparator

Other

Arm Label

Low Field Magnetic Stimulation

Sham (LFMS)

Crossover Arm

Arm Description

Patients in this arm will receive 2 days of active low field magnetic stimulation (LFMS) in phase 1, followed by 2 days of active low field magnetic stimulation (LFMS) in phase 2. LFMS is a novel, non-contact neuromodulation technique. LFMS is administered through a device while the patient lies on his/her back for 20 minutes.

Patients in this arm will receive 2 days of sham (not active) low field magnetic stimulation (LFMS) in phase 1, followed by 2 days of sham (not active) low field magnetic stimulation (LFMS) in phase 2.

Patients in this group will receive two days of sham (not active) low field magnetic stimulation (LFMS) in phase 1, followed by two days of active low field magnetic stimulation (LFMS) in phase 2.

Outcomes

Primary Outcome Measures

Hamilton Rating Scale for Depression - 6 Items
The total HAM-D-6 score is reported. The range of possible scores on the HAM-D-6 is from 0 to 22. Higher values indicate increased depression severity, and worse outcomes. This instrument is completed with a structured interview guide by the clinician based on his/her assessment of the patient's symptoms. This structured interview has been validated for use with time frames shorter than one week.The time frame for this scale is the past 24 hours.

Secondary Outcome Measures

Full Information

First Posted
July 30, 2012
Last Updated
August 2, 2017
Sponsor
Massachusetts General Hospital
Collaborators
National Institute of Mental Health (NIMH), Yale University, Icahn School of Medicine at Mount Sinai, University of Texas Southwestern Medical Center, University of Alabama at Birmingham, Emory University
search

1. Study Identification

Unique Protocol Identification Number
NCT01654796
Brief Title
Trial of Low Field Magnetic Stimulation Augmentation of Antidepressant Therapy in Treatment-Resistant Depression
Acronym
RAPID
Official Title
Double-Blind, Proof-of-Concept (POC) Trial of Low Field Magnetic Stimulation (LFMS) Augmentation of Antidepressant Therapy in Treatment-Resistant Depression
Study Type
Interventional

2. Study Status

Record Verification Date
August 2017
Overall Recruitment Status
Completed
Study Start Date
April 2013 (Actual)
Primary Completion Date
May 2016 (Actual)
Study Completion Date
September 2016 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Massachusetts General Hospital
Collaborators
National Institute of Mental Health (NIMH), Yale University, Icahn School of Medicine at Mount Sinai, University of Texas Southwestern Medical Center, University of Alabama at Birmingham, Emory University

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
This study is looking at the safety and efficacy of low field magnetic stimulation (LFMS) for treating patients with treatment resistant depression who are taking an antidepressant that is not working for them.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Treatment Resistant Depression
Keywords
Depression, Treatment Resistant Depression

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
84 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Low Field Magnetic Stimulation
Arm Type
Active Comparator
Arm Description
Patients in this arm will receive 2 days of active low field magnetic stimulation (LFMS) in phase 1, followed by 2 days of active low field magnetic stimulation (LFMS) in phase 2. LFMS is a novel, non-contact neuromodulation technique. LFMS is administered through a device while the patient lies on his/her back for 20 minutes.
Arm Title
Sham (LFMS)
Arm Type
Placebo Comparator
Arm Description
Patients in this arm will receive 2 days of sham (not active) low field magnetic stimulation (LFMS) in phase 1, followed by 2 days of sham (not active) low field magnetic stimulation (LFMS) in phase 2.
Arm Title
Crossover Arm
Arm Type
Other
Arm Description
Patients in this group will receive two days of sham (not active) low field magnetic stimulation (LFMS) in phase 1, followed by two days of active low field magnetic stimulation (LFMS) in phase 2.
Intervention Type
Device
Intervention Name(s)
Low Field Magnetic Stimulation (LFMS)
Intervention Description
The LFMS devices produces a unique magnetic field that may help alleviate symptoms of depression.
Intervention Type
Device
Intervention Name(s)
Sham LFMS
Intervention Description
Sham LFMS looks and sounds like the active treatment but does not produce any magnetic stimulation.
Primary Outcome Measure Information:
Title
Hamilton Rating Scale for Depression - 6 Items
Description
The total HAM-D-6 score is reported. The range of possible scores on the HAM-D-6 is from 0 to 22. Higher values indicate increased depression severity, and worse outcomes. This instrument is completed with a structured interview guide by the clinician based on his/her assessment of the patient's symptoms. This structured interview has been validated for use with time frames shorter than one week.The time frame for this scale is the past 24 hours.
Time Frame
Baseline and 48 hours after initiating treatment

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Male or female, 18-65 years old Diagnosed with Major Depressive Disorder (MDD) and currently experiencing a Major Depressive Episode (MDE) of at least eight weeks A participant has Treatment Resistant Depression (TRD) of the current MDE Good general health For female participants, status of non-childbearing potential or use of an acceptable form of birth control Body mass index between 18-40 kg/m2 Concurrent psychotherapy will be allowed if the type and frequency of the therapy has been stable for at least three months prior to screening and is expected to remain stable during participation in the study Concurrent hypnotic therapy will be allowed if the therapy has been stable for at least 4 weeks prior to screening and is expected to remain stable during the subject's participation in the study Participant must be able to lie flat for 20 minutes Exclusion Criteria: A woman of childbearing potential who is not willing to use one of the specified forms of birth control during the study Pregnant or breastfeeding A woman with a positive pregnancy test at screening or baseline Participant has TRD of the current MDE with failure to achieve a satisfactory response, as perceived by the subject, to more than 3 treatment courses of a therapeutic dose of an antidepressant therapy of at least eight weeks duration Participant has a current diagnosis of a Substance Use Disorder with the exception of nicotine dependence, at screening or within six months prior to screening Current diagnosis of Axis I disorders other than Generalized Anxiety Disorder, Social Anxiety Disorder, Panic Disorder, Specific Phobia, Post Traumatic Stress Disorder or Complicated Grief (unless one of these is comorbid and clinically unstable, and/or the focus of the participant's treatment for the past six months or more). Subject has a history of schizophrenia or schizoaffective disorders, any history of psychotic symptoms or is on antipsychotic medication for the treatment of psychotic symptoms Subject has a history of eating disorders within five years of screening Subject has any Axis I or Axis II Disorder, which at screening is clinically predominant to their MDD or has been predominant at any time within six months prior to screening The participant is considered at significant risk for suicide during the study Subject has had electroconvulsive therapy in the current episode of depression Subject has had Transcranial Magnetic Stimulation or has received treatment with other experimental devices for the treatment of the current episode of depression Subject has received Vagus Nerve Stimulation at any time Dementia, delirium, amnestic, or other cognitive disorders There is a clinically significant abnormality on the screening physical examination Participation in any clinical trial with an investigational drug or device within the past month or concurrent to study participation Known history or current episode of: --Uncontrolled hypertension, Recent myocardial infarction (within one year) or a history of more than one myocardial infarction, Syncopal event within the past year, Congestive heart failure, Angina pectoris Lifetime history of surgical procedures involving the brain or meninges, encephalitis, meningitis, degenerative central nervous system disorder (e.g., Alzheimer's or Parkinson's Disease), epilepsy, mental retardation, any other disease/procedure/accident/intervention associated with significant injury to or malfunction of the central nervous system, or a history of significant head trauma within the past two years. Lab abnormalities are present History of hypothyroidism and has been on a stable dosage of thyroid replacement medication for less than six months prior to screening Hisotry of hyperthyroidism which was treated (medically or sugically) less than six months prior to screening Any current or past history of any physical condition which in the investigator's opinion might put the subject at risk or interfere with the interpretation of study results History of positive screening urine test for drugs of abuse Patient with any non-removable stimulation device such as neurostimulators, pacemakers and cochlear implants Patients requiring treatment with excluded concomitant medications Patients who cannot be in a MRI Patients who are currently using a metal intrauterine device (IUD)
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Dan Iosifescu, MD
Organizational Affiliation
Mount Sinai School of Medecine
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Gerald Sanacora, MD
Organizational Affiliation
Yale University
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Madhukar Trivedi, MD
Organizational Affiliation
University of Texas
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Maurizio Fava, MD
Organizational Affiliation
Massachusetts General Hospital (Coordinating Center)
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Mark Rapaport, MD
Organizational Affiliation
Emory University
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Richard Shelton, MD
Organizational Affiliation
Univsity of Alabama at Birmingham
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
George I Papakostas, MD
Organizational Affiliation
Massachusetts General Hospital
Official's Role
Principal Investigator
Facility Information:
Facility Name
University of Alabama at Birmingham
City
Birmingham
State/Province
Alabama
ZIP/Postal Code
35205
Country
United States
Facility Name
Yale University
City
New Haven
State/Province
Connecticut
ZIP/Postal Code
06511
Country
United States
Facility Name
Emory University
City
Atlanta
State/Province
Georgia
ZIP/Postal Code
30322
Country
United States
Facility Name
Massachusetts General Hospital
City
Boston
State/Province
Massachusetts
ZIP/Postal Code
02114
Country
United States
Facility Name
Mount Sinai School of Medecine
City
New York
State/Province
New York
ZIP/Postal Code
10029
Country
United States
Facility Name
University of Texas Southwestern
City
Dallas
State/Province
Texas
ZIP/Postal Code
75390
Country
United States

12. IPD Sharing Statement

Learn more about this trial

Trial of Low Field Magnetic Stimulation Augmentation of Antidepressant Therapy in Treatment-Resistant Depression

We'll reach out to this number within 24 hrs